Novartis announced data from PSMAddition demonstrating improved prostate-specific antigen responses with Pluvicto (lutetium (177Lu) vipivotide tetraxetan) combined with standard-of-care in PSMA-positive metastatic hormone sensitive prostate cancer.
Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.
